Department of Medical Oncology;
Canberra Region Cancer Centre;
The Canberra Hospital;
Canberra;
ACT 2605;
Australia;
Department of Gastroenterology;
The Canberra Hospital;
Canberra;
ACT 2605;
Australia;
ANU Medical School;
Australian National University;
Canberra;
ACT 2601;
Australia;
Department of Anatomical Pathology;
The Canberra Hospital;
Canberra;
ACT 2605;
Australia;
Ipilimumab; Nivolumab; Metastatic; melanoma; Steroid-refractory; colitis; Infliximab-refractory; colitis; Vedolizumab; Case; report;